{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218250","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-05-12T12:15:16+00:00","discovered_at":"2026-05-12T12:20:00.334864+00:00","generated_at":"2026-05-12T12:22:15.980728+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path","bullets":["Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.","Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.","Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.","Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218250","json":"https://secwatch.observer/filing/0001193125-26-218250.json","markdown":"https://secwatch.observer/filing/0001193125-26-218250.md","text":"https://secwatch.observer/filing/0001193125-26-218250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/0001193125-26-218250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/crbp-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:22:15.980728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d7170cfa0025e2c05c9ecf1ac1ca222a93def2","claim":"Corbus Pharmaceuticals Holdings, Inc. reported first quarter ended March 31, 2026 results: net income net loss of approximately $23.0 million, EPS net loss per basic and diluted share of $1.23.","evidence_excerpt":"Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/0001193125-26-218250-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of approximately $23.0 million"},{"label":"EPS","value":"net loss per basic and diluted share of $1.23"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}